Synergistic enhancement of efferocytosis and cholesterol efflux via macrophage biomimetic nanoparticle to attenuate atherosclerosis progression

Shiteng Cai, Jinfeng Gao, Xueyi Weng, Zhengmin Wang, Dong Zheng, Qiaozi Wang, Qiyu Li, Chengzhi Han, Weiyan Li, Jing Chen, Yuyuan Fu, Yiwen Tan, Bo Wei, Zhiqing Pang, Zheyong Huang, Yanan Song, Junbo GeBioactive 2025 · DOI

TL;DR

This paper introduces R@MLP, a novel biomimetic nanoparticle that simultaneously blocks the "don't eat me" signal (CD47-SIRPα axis) and promotes cholesterol efflux from macrophages. This dual-action approach significantly enhances the clearance of apoptotic cells in atherosclerotic plaques, shifting macrophages to an anti-inflammatory state and attenuating disease progression in mouse models.

What Problem Does This Paper Address?

Atherosclerosis, a chronic inflammatory disease leading to heart attacks and strokes, is characterized by the buildup of lipid-laden foam cells and apoptotic cells in artery walls. While therapies targeting the CD47-SIRPα "eat me not" signal have shown promise in clearing these cells, they are limited by the overwhelming lipid burden within plaque macrophages. This excess cholesterol impairs efferocytosis and can even activate inflammatory pathways, hindering therapeutic efficacy. The paper addresses this by developing a strategy that not only enhances the clearance of apoptotic cells but also actively helps macrophages manage their lipid load.

Methods

The core innovation is the development of retinoic acid-loaded macrophage membrane-biomimetic liposomes (R@MLP).

  • Macrophage Membrane Camouflage: Liposomes were coated with membranes derived from macrophages. This "biomimetic" approach allows the nanoparticles to target inflammatory sites and interact with immune cells.
  • CD47-SIRPα Blockade: The macrophage membrane naturally contains SIRPα. When R@MLP encounters apoptotic cells expressing CD47, the SIRPα on the nanoparticle surface competitively binds to CD47, effectively blocking the "don't eat me" signal and promoting efferocytosis (phagocytosis of apoptotic cells).
  • Retinoic Acid Delivery: The liposomes encapsulate retinoic acid (RA). Once inside macrophages, RA activates liver X receptors (LXRs), which in turn upregulate the expression of ABCA1 and ABCG1. These proteins are crucial for cholesterol efflux, helping macrophages to clear excess lipids.
  • In Vitro and In Vivo Assays: The researchers used cell cultures (macrophages, endothelial cells) and ApoE-/- mouse models of atherosclerosis to evaluate the nanoparticles' targeting ability, efferocytosis enhancement, cholesterol efflux promotion, inflammatory marker modulation, and overall anti-atherosclerotic efficacy. Techniques included confocal microscopy, flow cytometry, Western blotting, qRT-PCR, and histological analysis of aortic tissues.

Datasets

Not discussed in the paper. The study relies on established cell lines (RAW264.7, HUVEC) and a standard mouse model (ApoE-/-) for atherosclerosis research.

Key Insights and Ideas

  • Synergistic Dual Action is Key: The most significant insight is that combining CD47-SIRPα blockade with cholesterol efflux promotion is far more effective than either strategy alone. This addresses the critical limitation of lipid overload in current efferocytosis-enhancing therapies.
  • Macrophage Mimicry for Targeting: Using macrophage membranes for nanoparticle coating provides a natural homing mechanism to inflammatory sites within atherosclerotic plaques, improving drug delivery efficiency.
  • Retinoic Acid as a Cholesterol Regulator: The study highlights retinoic acid's role in activating LXR pathways to boost cholesterol efflux, a crucial but often overlooked aspect of macrophage health in atherosclerosis.
  • Shifting Macrophage Phenotype: Beyond simply clearing debris, R@MLP effectively shifts macrophages from a pro-inflammatory to an anti-inflammatory state, contributing to plaque stabilization.

Key Results

  • Enhanced Efferocytosis: R@MLP significantly increased the phagocytic clearance of apoptotic cells by macrophages in vitro and in vivo.
  • Promoted Cholesterol Efflux: R@MLP treatment led to a substantial increase in cholesterol efflux from macrophages, with the efflux ratio reaching 77.98% ± 5.79% in the R@MLP group, compared to ~20-30% in control groups.
  • Reduced Plaque Formation: In ApoE-/- mice, R@MLP treatment significantly reduced atherosclerotic plaque area by approximately 70% compared to the PBS control group.
  • Improved Plaque Stability: R@MLP treatment led to increased collagen content and a thicker fibrous cap in atherosclerotic plaques, indicating improved stability.
  • Anti-inflammatory Shift: R@MLP treatment modulated inflammatory gene expression, decreasing pro-inflammatory cytokines and increasing anti-inflammatory markers in aortic tissues.
  • Biocompatibility: R@MLP demonstrated good biocompatibility in healthy mice, with no significant organ damage or adverse inflammatory responses observed.

Limitations and Future Work

  • Systemic Lipid-Lowering Therapy: The authors acknowledge that R@MLP primarily targets macrophage lipid metabolism and does not significantly impact systemic lipid levels. Therefore, adjunct systemic lipid-lowering therapy might still be necessary for comprehensive management.
  • Batch-to-Batch Variability: The composition of donor macrophage membranes could lead to variability in nanoparticle targeting and function, necessitating stringent quality control for clinical translation.
  • Future Directions: The researchers plan to evaluate R@MLP in large-animal atherosclerosis models and explore catheter-based local delivery methods to maximize intraplaque exposure while minimizing systemic burden.

Summary updated

Abstract

Atherosclerosis is the leading cause of myocardial infarction and stroke, which is characterized as a chronic inflammatory disease due to the aberrant accumulation of apoptotic cells in the necrotic core. Previous CD47-SIRPα checkpoint blockage strategies based on monoclonal antibodies or nanoparticles have shown significant pro-efferocytosis effects and thus improved the inflammatory microenvironment of plaque. However, apoptotic foam cells and concentrated cholesterol render plaque macrophages an overwhelming lipid burden, limiting the pro-efferocytosis effect of checkpoint blockade therapy in atherosclerosis. In this study, we fabricate a retinoic acid-loaded macrophage membrane-biomimetic liposome (R@MLP) to improve the efferocytosis ability of macrophages further. Mechanistically, the innate existence of SIRPα on the R@MLP would block the binding of CD47 on apoptotic cells with SIRPα on macrophages to realize the CD47-SIRPα inhibition. Consequently, engulfing retinoic acid in R@MLP would upregulate the expression of ABCA1 and ABCG1 of macrophages and enhance cholesterol efflux. In the mouse model of atherosclerosis, which benefited from the macrophage membrane, R@MLP showed ideal inflammation targeting ability to plaques and further reinforced the efferocytosis ability of macrophages. Ultimately, R@MLP shifted macrophages to the anti-inflammatory state and attenuated the progression of atherosclerosis. R@MLP synergizes checkpoint inhibition and cholesterol efflux to boost pro-efferocytosis therapy and presents a novel anti-inflammatory therapeutic strategy for atherosclerosis management.
BibTeX
@inproceedings{cai2025synergistic,
  author = {Shiteng Cai and Jinfeng Gao and Xueyi Weng and Zhengmin Wang and Dong Zheng and Qiaozi Wang and Qiyu Li and Chengzhi Han and Weiyan Li and Jing Chen and Yuyuan Fu and Yiwen Tan and Bo Wei and Zhiqing Pang and Zheyong Huang and Yanan Song and Junbo Ge},
  title = {{Synergistic enhancement of efferocytosis and cholesterol efflux via macrophage biomimetic nanoparticle to attenuate atherosclerosis progression}},
  booktitle = {Bioactive},
  year = {2025},
  doi = {10.1016/j.bioactmat.2025.09.022},
}
Figure